{"id":43498,"date":"2025-10-15T22:10:00","date_gmt":"2025-10-15T14:10:00","guid":{"rendered":"https:\/\/flcube.com\/?p=43498"},"modified":"2025-10-15T22:10:01","modified_gmt":"2025-10-15T14:10:01","slug":"pacific-shuanglins-controlling-stake-transferred-to-cnbg-in-rmb-4-7b-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43498","title":{"rendered":"Pacific Shuanglin’s Controlling Stake Transferred to CNBG in RMB 4.7B Deal"},"content":{"rendered":"\n

Pacific Shuanglin Bio-pharmacy Co., Ltd. (SHE: 000403<\/a>), a China-based blood products company, announced that its controlling shareholder, ShengBang Yinghao, has signed a Share Transfer Agreement with China National Biotec Group (CNBG). The agreement involves the transfer of ShengBang Yinghao’s total holding of 21.03% of Pacific Shuanglin’s shares to CNBG.<\/p>\n\n\n\n

Transaction Details<\/strong>
The total transfer price for the shares is approximately RMB 4.699 billion, with a per-share transfer price of approximately RMB 23.51. The entire consideration will be paid in cash.<\/p>\n\n\n\n

Change of Control<\/strong>
Upon completion of the transfer, Pacific Shuanglin’s controlling shareholder will change from ShengBang Yinghao to CNBG. The actual controller will shift from the Shaanxi Provincial People’s Government State-owned Assets Supervision and Administration Commission to China National Pharmaceutical Group Co., Ltd. (Sinopharm).<\/p>\n\n\n\n

Company Background and Future Impact<\/strong>
Pacific Shuanglin, formerly known as Yichun Engineering Machinery Co., Ltd., was officially renamed on March 30, 2021. The company focuses on the research, development, and sale of blood products. Post-acquisition, CNBG’s share of controlled plasma resources in China will exceed 30%, and it will hold 9 blood product licenses.-Fineline Info & Tech<\/a><\/p>\n\n\n\n